glp-1 receptor agonists and cardiovascular outcome trials an update Protective Properties of Agonists: More than Just Diabetic Weight Loss Drugs GLP-1 Receptor Agonists in Heart
Description
17 Periods of protection from patents and exclusivities overlap, and both can block the FDA from approving generic versions of brand-name products
John M, Kalra S, Nair T
Mounjaro (tirzepatide) : Approved by the FDA in 2022 for the management of type 2 diabetes
Adiponectin also decreases hepatic de novo glucose production and reduces free fatty acid levels in the liver (196), thereby mitigating hepatic steatosis, enhancing insulin sensitivity, and improving the circulating lipid profile ( Figure 1 Section E)
Injections are a very effective way to take medication
10.1016/j.biopha.2019.109138 83 MacDonaldP
